Funding for this research was provided by:
State Key Research Development Program of China (2019YFC1200501)
National Major Project for Control and Prevention of Infectious Disease in China (2018ZX10301101-004)
the emergency grants for prevention and control of SARS-CoV-2 of Ministry of Science and Technology (2020YFC0841400)
the emergency grants for prevention and control of SARS-CoV-2 of Guangdong Province (2020B111107001, 2020B111108001, 2018B020207013)
Guangdong Provincial Key Laboratory of Genome Read and Write (2017B030301011)
Guangdong Provincial Academician Workstation of BGI Synthetic Genomics Clinical Animal Diseases (2017B090904014)
Shenzhen Engineering Laboratory for Innovative Molecular Diagnostics (DRC-SZ884)
National Science and Technology Major Project of China (2017ZX10303406)
Received: 27 March 2020
Accepted: 10 June 2020
First Online: 30 June 2020
Ethics approval and consent to participate
: Informed consent was obtained from all participants enrolled in studies at the First Affiliated Hospital of Guangzhou Medical University. In addition, the study conformed to the principles of the Declaration of Helsinki. The IRB of BGI-Shenzhen approved the sequencing and downstream analyses of samples collected by the aforementioned institution under ethical clearance no. BGI-IRB 20008.
: Not applicable
: L.Y., Y.Z., F.C., and X.X. have applied for a patent relating to the amplicon-based method, and the details can be found below:PCR primer pair and application thereofPatent applicant: MGI Tech Co., LtdName of inventor(s): Lin Yang, Ya Gao, Guodong Huang, Yicong Wang, Yuqian Wang, Yanyan Zhang, Fang Chen, Na Zhong, Hui Jiang, Xun XuApplication number: PCT/CN2017/089195The remaining authors declare that they have no competing interests.